|
Is calling on Congress President JonLeibowitz Health Insurance Reform legislation to add the corresponding terms in order to save American consumers hundreds of dollars per year under Drugs Overhead. They asked Congress to block the following business transactions: the brand drug manufacturers to delay low-cost Generic (Or generic) competition from, directly or indirectly, generic drug manufacturers to pay a compensation fee. U.S. House of Representatives version of the medical reform bill actually contains a prohibition of such acts initiatives. Congressional Budget Office estimates that this provision of the House of Representatives is expected in the next 10 years, saving 1.8 billion U.S. dollars for the government health care costs (drug costs federal government spending only). The Senate version of the medical reform bill does not contain such prohibition. However, late last month, led by Wisconsin Senator HerbKohl the nine Democrats has already sent a letter to Senate Majority Leader HarryReid, urging the Senate to ban included in the final of the medical reform bill. Reid's aides declined to comment on the matter, while the Senate has not responded. Recent years, critics say, branded and generic manufacturers of commercial transactions between the various generic drugs significantly slowed the pace of the listing, which includes Anti-cancer drugs Material, antidepressants and antacids. FTC estimates that these transactions so that U.S. consumers now spending 3.5 billion U.S. dollars per year Medicine Fee. From the Maryland congressional Democrats ChrisVanHollen is proposed to prohibit such business transactions of the House of Representatives. He said that these transactions is actually a mutual collusion, manipulation of the market price of drugs, which means that consumers buy drugs for them to pay more. Critics say such deals are becoming a routine behavior of the pharmaceutical industry and the monopoly the prices of medicine production. Market research firm IMS Health says that in America, though generic drugs accounted for the total Sell For nearly 3 / 4, but consumer spending in the United States, drug costs, which account for only about 22% share. This means that the United States, 78% of drugs bill for the purchase of drugs accounted for 25% market share of branded products. However, the branded and generic drug manufacturers, said the representatives were to reach such a commercial transaction, lawfully, to resolve them quickly between the time-consuming and costly patent litigation. In addition, the generic industry trade group Association (GPhA) President KathleenJaeger of the critics of such commercial transactions known as "suspension of benefits transactions (payfordelay)" to be a rebuttal. She said the two sides reached a settlement so that generic manufacturers are usually entitled to a brand drugs will lose patent protection before they enter the market, allowing large consumers to buy cheaper earlier drugs. Such compensation stage a private transaction costs, it is legitimate, it is like generic drug companies to brand manufacturers supply API So. However, FTC Chairman JonLeibowitz that many violations of the antitrust settlement agreement, these generous Cooperation Agreement on the one hand limits the generic into the market, on the other hand increased the burden on consumers. In the FTC view, this is the health care of the most serious violations should be stopped. However, since 2005, several U.S. courts have recognized some of these business transactions. The court ruled that, when the settlement agreement to allow generic versions of brand drugs enter the market before the patent is about to expire, they do not violate the antitrust laws. We are high quality suppliers, our products such as LED Industrial Lighting , LED Flood Lighting for oversee buyer. To know more, please visits LED Downlights Dimmable.
Related Articles -
LED Industrial Lighting, LED Flood Lighting,
| 
